Creating targeted treatments for acute myeloid leukemia that avoid harmful side effects
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance
This study is working on new treatments for acute myeloid leukemia (AML) that aim to be more effective and have fewer side effects, helping patients feel better while fighting their cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10997434 on NIH RePORTER |
What this research studies
This research focuses on developing new FLT3 inhibitors that are effective against acute myeloid leukemia (AML) while minimizing harmful side effects like myelosuppression. The team is using advanced molecular tools to study how these inhibitors can overcome resistance mechanisms that often limit treatment success. By investigating the biology of leukemia and the mutations that drive it, the researchers aim to create therapies that improve patient outcomes. This work builds on previous successes in targeting similar pathways in other blood cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those with FLT3 mutations.
Not a fit: Patients with other types of leukemia or those without FLT3 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown success in targeting similar pathways in other myeloid malignancies, indicating a promising approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Shah, Neil P — University of California, San Francisco
- Study coordinator: Shah, Neil P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.